Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Alberto PapiMichael G IsonJoanne M LangleyDong-Gun LeeIsabel Leroux-RoelsFederico Martinon-TorresTino F SchwarzRichard N van Zyl-SmitLaura CamporaNancy DezutterNathalie de SchrevelLaurence FissetteMarie-Pierre DavidMarie Van der WielenLusine KostanyanVeronica Hulstrømnull nullPublished in: The New England journal of medicine (2023)
A single dose of the RSVPreF3 OA vaccine had an acceptable safety profile and prevented RSV-related acute respiratory infection and lower respiratory tract disease and severe RSV-related lower respiratory tract disease in adults 60 years of age or older, regardless of RSV subtype and the presence of underlying coexisting conditions. (Funded by GlaxoSmithKline Biologicals; AReSVi-006 ClinicalTrials.gov number, NCT04886596.).